The Global Bispecific Antibodies Market is valued at US$ 16.55 billion in 2025 and is projected to reach US$ 449 billion by 2034, expanding at a CAGR of 42.3% from 2025 to 2034. The market is experiencing rapid growth as pharmaceutical and biotechnology companies advance next-generation antibody therapies for cancer, autoimmune diseases, inflammatory conditions, hemophilia, ophthalmic diseases, and other complex conditions.

Bispecific Antibodies Market Overview

Bispecific antibodies are engineered molecules designed to interact with two different targets or antigens simultaneously. This dual-targeting capability can help activate immune cells against cancer, address multiple disease pathways, or improve therapeutic targeting.

The market encompasses the research, clinical development, manufacturing, and commercialization of different bispecific-antibody formats. Increasing investment in biologics manufacturing and clinical development is also supporting the transition of bispecific therapies from research programs toward clinical and commercial applications.

In May 2026, AGC Biologics launched a bispecific-antibody process development and manufacturing initiative with South Korea-based Novelty Nobility. The project involves NN4101, a bispecific antibody targeting retinal neovascular diseases, and is intended to progress from cell-line development and master cell bank generation in Copenhagen to GMP manufacturing in Chiba, Japan.

Key Factors Driving Market Growth

The Bispecific Antibodies Market is being supported by:

• Growing development of targeted immunotherapies
• Increasing oncology research and clinical development
• Expansion of bispecific antibody applications beyond cancer
• Growing investment in biologics manufacturing
• Increasing clinical development of next-generation antibody formats
• Rising demand for specialized therapies

North America Bispecific Antibodies Market

North America is a prominent region in the market, supported by advanced oncology research infrastructure, pharmaceutical companies, biologics manufacturing capabilities, clinical research networks, and regulatory frameworks.

According to the information provided, North America accounted for 48.8% of the global bispecific antibodies market in 2026. More than 180 bispecific antibody programs are under clinical development globally, with a substantial number led by companies based in the United States.

In January 2026, Vir Biotechnology, Inc. reported updated Phase 1 data for VIR-5500, a dual-masked PSMA×CD3 bispecific T-cell engager being investigated for metastatic prostate cancer. The study included 58 patients and reported antitumor activity.

Market Segmentation

The Bispecific Antibodies Market is segmented by:

• Product
• Mechanism of Action
• Route of Administration
• Application
• End User

Get the Complete Market Research Report

The Bispecific Antibodies Market Report by RNP Market Research provides insights into market size, growth trends, segmentation, regional analysis, clinical developments, competitive activity, and emerging opportunities.

Looking for detailed market data or customized research? Contact RNP Market Research to discuss your requirements.

Source: RNP Market Research